DxS to Team with BMS, ImClone on Erbitux Dx | GenomeWeb

NEW YORK (GenomeWeb News) – DxS will collaborate with drug developers Bristol-Myers Squibb and Eli lilly subsidiary ImClone Systems to continue development of a companion diagnostic for the drug cetuximab, which is marketed as Erbitux, in the US and Canada, DxS said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.